HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nivea promotes "Love, Hugs and Kisses" in Times Square

This article was originally published in The Rose Sheet

Executive Summary

Beiersdorf's Nivea brand sponsored New York's Times Square for New Year's Eve for the second year, urging people to "make 2010 a year of love, hugs and kisses." Celebrity pair Nick Lachey and Vanessa Minnillo - "one of America's most romantic couples" - hosted Nivea's Kiss Platform and helped ring in the New Year. "As a brand, Nivea values the importance of human connections, which is why there is no better place to be than Times Square on New Year's, where the whole world comes together to celebrate the start of 2010," says Marketing VP Nicolas Maurer. Move reflects Beiersdorf's stated aim to gain recognition and market share in the U.S. Sales of Nivea and Eucerin reached $335 million in the U.S. last year, but Beiersdorf's American operations are still not profitable (1"The Rose Sheet" Nov. 16)

You may also be interested in...



Beiersdorf Sets Sights On Growing U.S. Market Share With NIVEA, Eucerin

Hamburg, Germany-based personal-care giant Beiersdorf is focused on increasing sales and growing market share in the U.S. despite the hamstrung economy

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel